← Eichor
Condition: Mss Metastatic Colorectal Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Mss Metastatic Colorectal Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-S
Phase 2 · 13 location(s) · Oncolytics Biotech · NCT07446322Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Phase 1/Phase 2 · 1 location(s) · Dan Feng · NCT07281716Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebreli
Phase 2 · 1 location(s) · The Fourth Affiliated Hospital of Zhejiang University School · NCT06282445GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06558773XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the
Phase 2 · 1 location(s) · yue junhan · NCT06176885Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS
Phase 2 · 1 location(s) · Fudan University · NCT06218810Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Phase 3 · 12 location(s) · Sun Yat-sen University · NCT05768503ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Phase 2 · 1 location(s) · Beijing Hospital · NCT06321081Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
Phase 2 · 2 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07718490A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigati
Phase 1/Phase 2 · 14 location(s) · BioNTech SE · NCT07079631Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tip
Phase 2 · 2 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT06522919A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colo
Phase 2 · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT06978400- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma
Phase 2 · 23 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT06856837Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
NA · 1 location(s) · The First People's Hospital of Changzhou · NCT06456515A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide i
Phase 2 · 1 location(s) · The First Hospital of Jilin University · NCT06979908Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorect
Phase 2/Phase 3 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT06958419FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorect
Phase 3 · 24 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06733038Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Fail
NA · 1 location(s) · Ningbo Medical Center Lihuili Hospital · NCT06613113PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Phase 2 · 11 location(s) · Biotheus Inc. · NCT07133750FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 33 location(s) · Parabilis Medicines, Inc. · NCT05919264Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-me
Phase 3 · 1 location(s) · Caigang Liu · NCT06566755A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Meta
Phase 2 · 2 location(s) · Fudan University · NCT05954429Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanc
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06764680Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Me
Phase 2 · 3 location(s) · Sun Yat-sen University · NCT05959356A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants Wi
Phase 1 · 11 location(s) · IDEAYA Biosciences · NCT07540572A Study of ASP1002 in Adults for Treatment of Solid Tumors
Phase 1 · 15 location(s) · Astellas Pharma Global Development, Inc. · NCT05719558Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Meta
Phase 2 · 1 location(s) · Dai, Guanghai · NCT06685276COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer
EARLY_Phase 1 · 1 location(s) · Biogenea Pharmaceuticals Ltd. · NCT07328087New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · The First Hospital of Jilin University · NCT07559760
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.